In­sil­i­co preps first can­di­date for IND stud­ies, hop­ing to launch tri­al in IPF by end of 2021

Over the last sev­er­al years, Alex Zha­voronkov has turned In­sil­i­co in­to one of the most well-con­nect­ed AI biotechs out there. Now, the Hong Kong-based com­pa­ny is one step clos­er to reach­ing the clin­ic.

In­sil­i­co is bring­ing its first can­di­date in­to IND-en­abling stud­ies, Zha­voronkov an­nounced Wednes­day, with the goal of launch­ing an in-hu­man tri­al at some point lat­er this year. The move marks what he says is a first in AI drug dis­cov­ery, as both the tar­get and small-mol­e­cule in­hibitor in­volved in the pro­gram are com­plete­ly new and AI-gen­er­at­ed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER